Navigation Links
Anti-cancer drug discovery partnership formed between UMMC and Ole Miss

JACKSON, Miss. A new partnership to search for cancer-fighting drugs combines compound-identification and screening expertise at the University of Mississippi's National Center for Natural Products Research with the drug development and clinical-trials capabilities at the University of Mississippi Medical Center Cancer Institute.

An agreement announced today between the Oxford-based NCNPR and the Cancer Institute in Jackson creates the Drug Discovery Core, which will be directed by Dr. David Pasco, assistant director of the Natural Products Center and research professor in pharmacognosy.

The drug discovery process begins at the NCNPR, where researchers collect plants and other natural products, create extracts and screens them for activity against given targets. Under the new agreement the most promising anti-cancer compounds will be further isolated and sent to Jackson for development and testing.

"Cancer institutes usually have some type of drug discovery program," Pasco said. "Since Dr. Miele's arrival, Dr. Larry Walker (director of the NCNPR) and I have been talking with him about this venture."

Dr. Lucio Miele took the Cancer Institute directorship in summer 2009. He's worked to expand the institute's research mission by hiring scientists, purchasing high-tech equipment and forging partnerships with other institutions. Founding the Drug Discovery Core is a milestone in that effort.

"Development of new anti-cancer agents is one of the most important aspects if not the most important aspect of cancer research," Miele said. "The Natural Products Center has tremendous experience and this agreement increases the synergy between our two campuses.

"Natural products are a rich source of drug discovery and have yielded some of the most potent drugs we still use -- the best example being Taxol," Miele said, referencing a drug that UM researchers had a hand in developing as the NCNPR was first forming.

Cancer research has advanced to the point where scientists have identified most genes and gene mutations responsible for causing cancer. Those are the targets of drug developers.

"There are several hundred genes identified," Pasco said. "But they all belong to about 12 different signal-transduction pathways."

Blocking those pathways with specially designed drugs can essentially keep genes from switching on or off.

In Oxford, Pasco and his team finished screening about 30 plant extracts this spring. Those extracts are used in traditional Chinese and Indian medicine, some with proven anti-cancer properties.

The screenings assessed the activity of each extract along the dozen or so pathways. About 25 extracts showed activity on the majority of the signaling pathways.

Lest the process seem overly simple, think of each pathway as a struck piano key. The note alone may not be significant, but played in sequence with others, it can create an ominous concerto a tumor.

Shutting down the concerto requires blocking several pathways at once. Hence, identifying natural products capable of blocking multiple pathways could be a major step in our quest for better cancer drugs.

"Specific collections of these pathways are involved in the expression of cancer," Pasco said. "And there's a lot of crosstalk among those pathways. That's what makes cancer so difficult to treat."

Investigators will search the screening results for unique patterns of activity among the various signaling pathways.

"Once we find an interesting extract, we can tear it down further to get at the active compound," Pasco said.

Sometimes it's multiple compounds that work together in one extract to make it promising. Getting to the core of that scenario is one of the NPNPR specialties, Miele said.

Ultimately, by combining several compounds, scientists in the Drug Discovery Core hope to create pharmaceuticals that act on a number of key pathways.

"Because cancer is so complicated, you need to use a range of compounds to prevent the tumors from becoming resistant to the compounds you're using," Pasco said.

Those combinations of compounds candidate drugs will be sent to UMMC labs in Jackson for testing on various cancer cell lines, Miele said. That phase of drug development is called in vitro testing, meaning in-glass.

Once proven in vitro, researchers would test the drugs on tumors in animal models likely mice or rats. The next phase would take candidate drugs to carefully regulated clinical trials administered by the Cancer Institute.


Contact: Jack Mazurak
University of Mississippi Medical Center

Related medicine news :

1. Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target
2. Scripps Research and MIT scientists discover class of potent anti-cancer compounds
3. Getting more anti-cancer medicine into the blood
4. Soft drink could enhance effects of an anti-cancer drug
5. Parkinsons disease: Excess of special protein identified as key to symptoms and possible new target for treatment with widely used anti-cancer drug imatinib
6. Researchers advance biosynthesis of potent anti-cancer drug Taxol
7. Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol
8. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
9. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
10. Program focuses on anti-cancer stem cell therapies
11. ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... An ... directory is specialized and only includes chiropractic clinics in the US. , The ... trustworthy alternative health practitioner when back pain sets in. When people are experiencing ...
(Date:11/30/2015)... ... November 30, 2015 , ... In ... Halloween festivities, the Word of Life Christian Church of Flint, MI, hosted a ... a giant 1.25 ton pile of candy dubbed “Candy Mountain”. , A Forever ...
(Date:11/30/2015)... ... November 30, 2015 , ... During ... fundraising campaign to raise funds for its research, education, support, and advocacy efforts. ... organization’s annual funding. , The Mesothelioma Applied Research Foundation, which also goes by ...
(Date:11/30/2015)... ... November 30, 2015 , ... The ... in Dallas, TX, on January 29 and 30, 2016. The course welcomes dental ... of their practices, to learn how to better succeed in the modern dental ...
(Date:11/30/2015)... ... November 30, 2015 , ... HemoTreat™ has announced that the ... ointment to its website. , “Our goal is simple:” says Michael Blasco, HemoTreat’s ... the comparison chart and ingredient list allows our customers to quickly see why, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... Free Press as a Top Workplace , among the ... work for in 2015. ... annually, based on employee surveys rating company leadership, career opportunities, ... based solely on employee feedback. The survey is conducted by ...
(Date:11/30/2015)...  IBA Molecular North America, Inc. (IBAMNA), a U.S. ... that as of January 1, 2016, it will do ... to rebrand the company reflects a refined vision for ... close relationship with Zevacor Molecular.  Both IBAMNA and Zevacor ... Peter Burke , Vice President Sales ...
(Date:11/30/2015)... 30, 2015 Baxalta Incorporated (NYSE: ... dedicated to delivering transformative therapies to patients ... today announced the launch and first shipments ... extended circulating half-life recombinant factor VIII (rFVIII) ... ADVATE [Antihemophilic Factor (Recombinant)]. The treatment was ...
Breaking Medicine Technology: